Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Dr. Bruce D. Car DACVP, Ph.D. |
IPO Date | July 24, 2013 |
Location | United States |
Headquarters | 88 Sidney Street, Cambridge, MA, United States, 02139-4169 |
Employees | 383 |
Sector | Healthcare |
Industry | Biotechnology |
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
NA
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email